Cell Free DNA Analysis for Chromosomal Abnormalities among Pregnant Females of Pakistan

Main Article Content

Aliya Irshad Sani
Sajjad Ali
Taha Sohail
Sadia Farrukh


The advancement of modern molecular biology techniques has made it possible to detect fetal anomalies beforehand in order to tackle the upcoming situation. However, the idea is to devise the most sensitive screening tools with fewer chances of errors as well as noninvasive methods to diagnose fetal abnormalities. Previously used methods amniocentesis and chorionic villus sampling possess risks for the fetus on the other hand cell free fetal DNA (cffDNA) method is less invasive and reduces the risk to fetus. However, currently most cffDNA screening tests routinely evaluate fetal sex and sex chromosomal aneuploidies while in developed countries analysis of cffDNA is incorporated in high-risk pregnancies to detect the defects and mutations. In Pakistan where the prevalence of birth defect is reported approximately 7% as well as increased consanguineous marriages increase the chance of such defects. Centers in Pakistan offer cffDNA testing but with a hefty cost on the pocket. This review highlights the importance and prospects of exploring the maternal plasma Cell-free DNA (cfDNA) screening in high risk mothers in Pakistan as well as the limitations and strengths of the technique. Since the cffDNA sequencing is a major advancement in genomic medicine that has reduced the invasive procedures in clinical medicine.

Cell free DNA, NIPT, aneuploidy, prenatal screening.

Article Details

How to Cite
Sani, A. I., Ali, S., Sohail, T., & Farrukh, S. (2020). Cell Free DNA Analysis for Chromosomal Abnormalities among Pregnant Females of Pakistan. Asian Journal of Biochemistry, Genetics and Molecular Biology, 4(3), 1-10. https://doi.org/10.9734/ajbgmb/2020/v4i330105
Minireview Article


Pös O, Budiš J, Szemes T. Recent trends in prenatal genetic screening and testing. F1000 Research. 2019;8.

Lo YD, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS. Presence of fetal DNA in maternal plasma and serum. The Lancet. 1997;350(9076): 485-7.

Lo YD, Hjelm NM, Fidler C, Sargent IL, Murphy MF, Chamberlain PF, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. New England Journal of Medicine. 1998;339(24):1734-8.

Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell‐free DNA in maternal blood in screening for fetal aneuploidies: Updated meta‐analysis. Ultrasound in Obstetrics & Gynecology. 2015;45(3):249-66.

Hussain S, Asghar I, Sabir MU, Chattha MN, Tarar SH, Mushtaq R. Prevalence and pattern of congenital malformations among neonates in the neonatal unit of a teaching hospital. J Pak Med Assoc. 2014;64(6): 629-34.

Gul F, Jabeen M, Khan AS. Frequency of congenital malformations and associated risk factors at Liaqat memorial hospital, Kohat. Khyber Medical University Journal. 2012;4(3).

Campbell ST, Wiencek JR. DNA sequencing in the clinical laboratory: A ladder to the future. Clinical Chemistry. 2018;64(4):757.

Guy C, Haji‐Sheikhi F, Rowland CM, Anderson B, Owen R, Lacbawan FL, Alagia DP. Prenatal cell‐free DNA screening for fetal aneuploidy in pregnant women at average or high risk: Results from a large US clinical laboratory. Molecular Genetics & Genomic Medicine. 2019;7(3):e545.

Bianchi DW. Cherchez la femme: Maternal incidental findings can explain discordant prenatal cell-free DNA sequencing results. Genetics in Medicine. 2018;20(9): 910-7.

Canick JA, Palomaki GE, Kloza EM, Lambert‐Messerlian GM, Haddow JE. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenatal Diagnosis. 2013;33(7):667-74.

Committee on Practice Bulletins—Obstetrics C. Practice Bulletin No. 163: Screening for Fetal Aneuploidy. Obstetrics and Gynecology. 2016;127(5):e123.

Minear MA, Lewis C, Pradhan S, Chandrasekharan S. Global perspectives on clinical adoption of NIPT. Prenatal Diagnosis. 2015;35(10):959-67.

Chiu RW, Chan KA, Gao Y, Lau VY, Zheng W, Leung TY, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proceedings of the National Academy of Sciences. 2008;105(51):20458-63.

Chen EZ, Chiu RW, Sun H, Akolekar R, Chan KA, Leung TY, Jiang P, Zheng YW, Lun FM, Chan LY, Jin Y. Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PloS One. 2011;6(7):e21791.

Costa JM, Benachi A, Gautier E. New strategy for prenatal diagnosis of X-linked disorders. New England Journal of Medicine. 2002;346(19):1502.

Rafi I, Hill M, Hayward J, Chitty LS. Non-invasive prenatal testing: Use of cell-free fetal DNA in Down syndrome screening. 2017;298-299.

Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, et al. Cell-free DNA analysis for noninvasive examination of trisomy. New England Journal of Medicine. 2015;372(17):1589-97.

Rava RP, Srinivasan A, Sehnert AJ, Bianchi DW. Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X. Clinical Chemistry. 2014;60(1):243-50.

Wald NJ, Lau KW, Bestwick JP, Old RW, Huttly WJ, Cheng R. Specifying a gold standard for the validation of fetal fraction estimation in prenatal screening. Clinical Chemistry. 2018;64(9):1394-9.

Haghiac M, Vora NL, Basu S, Johnson KL, Presley L, Bianchi DW, De Mouzon SH. Increased death of adipose cells, a path to release cell‐free DNA into systemic circulation of obese women. Obesity. 2012;20(11):2213-9.

Bianchi DW, Chiu RW. Sequencing of circulating cell-free DNA during pregnancy. New England Journal of Medicine. 2018;379(5):464-73.

Hartwig TS, Ambye L, Sørensen S, Jørgensen FS. Discordant non‐invasive prenatal testing (NIPT)–a systematic review. Prenatal Diagnosis. 2017;37(6): 527-39.

Gregg AR, Skotko BG, Benkendorf JL, Monaghan KG, Bajaj K, Best RG, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: A position statement of the American College of Medical Genetics and Genomics. Genetics in Medicine. 2016;18(10):1056.

Benn P, Borrell A, Chiu RW, Cuckle H, Dugoff L, Faas B, et al. Position statement from the chromosome abnormality screening committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenatal Diagnosis. 2015;35(8):725-34.

Curnow KJ, Wilkins-Haug L, Ryan A, Kırkızlar E, Stosic M, Hall MP, et al. Detection of triploid, molar and vanishing twin pregnancies by a single-nucleotide polymorphism–based noninvasive prenatal test. American Journal of Obstetrics and Gynecology. 2015;212(1):79-e1.

Bianchi DW. Pregnancy: Prepare for unexpected prenatal test results. Nature News. 2015;522(7554):29.

Wang Y, Chen Y, Tian F, Zhang J, Song Z, Wu Y, et al. Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clinical Chemistry. 2014;60(1):251-9.

Bianchi DW, Chudova D, Sehnert AJ, Bhatt S, Murray K, Prosen TL, et al. Noninvasive prenatal testing and incidental detection of occult maternal malignancies. JAMA. 2015;314(2):162-9.

Dharajiya NG, Grosu DS, Farkas DH, McCullough RM, Almasri E, Sun Y, et al. Incidental detection of maternal neoplasia in noninvasive prenatal testing. Clinical Chemistry. 2018;64(2):329-35.

Verhoef TI, Hill M, Drury S, Mason S, Jenkins L, Morris S, Chitty LS. Non‐invasive prenatal diagnosis (NIPD) for single gene disorders: Cost analysis of NIPD and invasive testing pathways. Prenatal Diagnosis. 2016;36(7):636-42.

Chiu EK, Hui WW, Chiu RW. cfDNA screening and diagnosis of monogenic disorders–where are we heading?. Prenatal Diagnosis. 2018;38(1):52-8.

Hui WW, Jiang P, Tong YK, Lee WS, Cheng YK, New MI, Kadir RA, Chan KA, Leung TY, Lo YD, Chiu RW. Universal haplotype-based noninvasive prenatal testing for single gene diseases. Clinical Chemistry. 2017;63(2):513-24.

Zhao L, Liang X, Huang H, Lan H, Wu X, Wang C. Prenatal diagnosis of β-thalassemia with cell-free fetal DNA in maternal plasma. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP. 2019;29(5):483-5.

Zhang L, Zhu Q, Wang H, Liu S. Count-based size-correction analysis of maternal plasma DNA for improved noninvasive prenatal detection of fetal trisomies 13, 18, and 21. American Journal of Translational Research. 2017;9(7):3469.

Stephanie CY, Chan KA, Zheng YW, Jiang P, Liao GJ, Sun H, Akolekar R, Leung TY, Go AT, van Vugt JM, Minekawa R. Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing. Proceedings of the National Academy of Sciences. 2014;111(23):8583-8.

Minear MA, Alessi S, Allyse M, Michie M, Chandrasekharan S. Noninvasive prenatal genetic testing: Current and emerging ethical, legal and social issues. Annual Review of Genomics and Human Genetics. 2015;16:369-98.

Hussain S, Asghar I, Sabir MU, Chattha MN, Tarar SH, Mushtaq R. Prevalence and pattern of congenital malformations among neonates in the neonatal unit of a teaching hospital. J Pak Med Assoc. 2014;64(6): 629-34.

Akolekar R, Beta J, Picciarelli G, Ogilvie C, D’Antonio F. Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: A systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2015;45:16–26.

Tamminga S, van Maarle M, Henneman L, Oudejans CBM, Cornel MC, Sistermans EA. Maternal plasma DNA and RNA sequencing for prenatal testing. Adv Clin Chem. 2016;74:63–102.

Erik A. Sistermans. The importance of reliable quality control materials for noninvasive prenatal testing. Clinical Chemistry. 2019;65(6):720–722.


Deans ZC, Allen S, Jenkins F, Khawaja F, Hastings R, Mann K, et al. Recommended practice for laboratory reporting of non-invasive prenatal testing (NIPT) of trisomies 13, 18 and 21: A consensus opinion. Prenat Diagn. 2017;37:699–704.

Deans ZC, Allen S, Jenkins L, Khawaja F, Gutowska-Ding W, Patton SJ, et al. Ensuring high standards for the delivery of NIPT world-wide: Development of an international external quality assessment scheme. Prenat Diagn. 2019;39:379–87.

Geeurickx E, Hendrix A. Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics. Molecular Aspects of Medicine. 2020;72:100828.

Bronkhorst AJ, Aucamp J, Pretorius PJ. Cell-free DNA: Preanalytical variables. Clin Chim Acta. 2015;450:243–53.

Romain Meddeb, Ekaterina Pisareva, Alain R. Thierry. Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA. Clinical Chemistry. 2019;65(5):623–633.


Nagy B. Cell-free nucleic acids in prenatal diagnosis and pregnancy-associated diseases. EJIFCC. 2019;30(2):215–223.

Skalis G, Katsi V, Miliou A, Georgiopoulos G, Papazachou O, Vamvakou G, et al. MicroRNAs in preeclampsia. MicroRNA. 2019;8(1):28-35.

Guarino E, Delli Poggi C, Grieco GE, Cenci V, Ceccarelli E, Crisci I, Sebastiani G, Dotta F. Circulating MicroRNAs as biomarkers of gestational diabetes mellitus: Updates and perspectives. International Journal of Endocrinology; 2018.

Park K. Park's textbook of preventive and social medicine. Preventive Medicine in Obstet, Paediatrics and Geriatrics; 2005.

Asindi AA, Al Hifzi I, Bassuni WA. Major congenital malformations among Saudi infants admitted to Asir Central Hospital. Annals of Saudi Medicine. 1997;17(2):250-3.

Gupta RK, Gupta CR, Singh D. Incidence of congenital malformations of the musculoskeletal system in live newborns in Jammu. JK Science. 2003;5:157-60.

Ahmed S, Jafri H, Rashid Y, Mason G, Ehsan Y, Ahmed M. Attitudes towards non‐invasive prenatal diagnosis among obstetricians in Pakistan, a developing, Islamic country. Prenatal Diagnosis. 2017;37(3):289-95.